CYTK
Cytokinetics Inc
NASDAQ · Biotechnology
$62.34
+2.10 (+3.49%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 20.17M | 31.51M | 700.83M | 617.31M | 631.19M |
| Net Income | -643,675,972 | -904,886,558 | 151.73M | 113.32M | 141.95M |
| EPS | — | — | — | — | — |
| Profit Margin | -3,191.1% | -3,031.6% | 21.7% | 18.4% | 22.5% |
| Rev Growth | -36.0% | -36.0% | +24.1% | +3.9% | +23.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.42B | 1.42B | 770.56M | 602.04M | 772.62M |
| Total Equity | 2.40B | 2.40B | 3.25B | 2.97B | 3.11B |
| D/E Ratio | 0.59 | 0.59 | 0.24 | 0.20 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -596,493,934 | -885,144,075 | 326.98M | 314.99M | 272.50M |
| Free Cash Flow | — | — | 119.78M | 143.60M | 140.08M |